These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

221 related items for PubMed ID: 10501915

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23. Effect of curcumin on cell cycle progression and apoptosis in vascular smooth muscle cells.
    Chen HW, Huang HC.
    Br J Pharmacol; 1998 Jul; 124(6):1029-40. PubMed ID: 9720770
    [Abstract] [Full Text] [Related]

  • 24. Comparative brain tissue distribution of camptothecin and topotecan in the rat.
    El-Gizawy SA, Hedaya MA.
    Cancer Chemother Pharmacol; 1999 Jul; 43(5):364-70. PubMed ID: 10100590
    [Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27. Effect of U-995, a potent shark cartilage-derived angiogenesis inhibitor, on anti-angiogenesis and anti-tumor activities.
    Sheu JR, Fu CC, Tsai ML, Chung WJ.
    Anticancer Res; 1998 Jul; 18(6A):4435-41. PubMed ID: 9891506
    [Abstract] [Full Text] [Related]

  • 28. Fisetin inhibits various attributes of angiogenesis in vitro and in vivo--implications for angioprevention.
    Bhat TA, Nambiar D, Pal A, Agarwal R, Singh RP.
    Carcinogenesis; 2012 Feb; 33(2):385-93. PubMed ID: 22139440
    [Abstract] [Full Text] [Related]

  • 29. Comparison of topoisomerase I inhibition, DNA damage, and cytotoxicity of camptothecin derivatives presently in clinical trials.
    Tanizawa A, Fujimori A, Fujimori Y, Pommier Y.
    J Natl Cancer Inst; 1994 Jun 01; 86(11):836-42. PubMed ID: 8182764
    [Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31. Intermittent exposure of medulloblastoma cells to topotecan produces growth inhibition equivalent to continuous exposure.
    Danks MK, Pawlik CA, Whipple DO, Wolverton JS.
    Clin Cancer Res; 1997 Oct 01; 3(10):1731-8. PubMed ID: 9815557
    [Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34. [Effects of CPUY013, a novel Topo I inhibitor, on human gastric adenocarcinoma BGC823 cells in vitro and in vivo].
    Ji YB, Zhou JH, Zuo MX, You QD.
    Yao Xue Xue Bao; 2008 Aug 01; 43(8):811-8. PubMed ID: 18956773
    [Abstract] [Full Text] [Related]

  • 35. In vitro and in vivo interaction between cisplatin and topotecan in ovarian carcinoma systems.
    Romanelli S, Perego P, Pratesi G, Carenini N, Tortoreto M, Zunino F.
    Cancer Chemother Pharmacol; 1998 Aug 01; 41(5):385-90. PubMed ID: 9523734
    [Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37. Vascular endothelial growth factor-toxin conjugate specifically inhibits KDR/flk-1-positive endothelial cell proliferation in vitro and angiogenesis in vivo.
    Ramakrishnan S, Olson TA, Bautch VL, Mohanraj D.
    Cancer Res; 1996 Mar 15; 56(6):1324-30. PubMed ID: 8640821
    [Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 12.